CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple...
Phase 1, Phase 2
New York, New York, United States and 2 other locations
in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment with a combination of dru...
Phase 2
New York, New York, United States
and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...
Phase 2
New York, New York, United States and 24 other locations
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma...
Phase 1, Phase 2
New York, New York, United States and 9 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Phase 1, Phase 2
Hackensack, New Jersey, United States and 48 other locations
study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple...
Phase 1
New York, New York, United States and 6 other locations
this study will be to assess the efficacy and safety of treating elderly patients with relapsed/refractory multiple myeloma with a...
Phase 2
New York, New York, United States
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...
Phase 1
New York, New York, United States and 9 other locations
of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...
Phase 2
New York, New York, United States and 40 other locations
The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant...
Phase 2
New York, New York, United States and 9 other locations
Clinical trials
Research sites
Resources
Legal